We are live on ! Find out more
LENZ

LENZ Therapeutics
LENZ

51 hedge funds and large institutions have $981M invested in LENZ Therapeutics in 2021 Q2 according to their latest regulatory filings, with 51 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

8.21% more ownership

Funds ownership: 0% → 8.21% (+8.2%)

Holders
51
Holders Change
+51
Holders Change %
–
% of All Funds
0.89%
Holding in Top 10
4
Holding in Top 10 Change
+4
Holding in Top 10 Change %
% of All Funds
0.07%
New
51
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
SB
Samsara BioCapital
California
+$185M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$93.6M
3
RCM
RA Capital Management
Massachusetts
+$67.1M
4
RSCM
Rock Springs Capital Management
Maryland
+$53.5M
5
VA
VR Adviser
New York
+$40.1M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
SB
1
Samsara BioCapital
California
$228M +$185M +1,061,660 New
Fidelity Investments
2
Fidelity Investments
Massachusetts
$111M +$93.6M +537,426 New
RCM
3
RA Capital Management
Massachusetts
$82.9M +$67.1M +385,481 New
RSCM
4
Rock Springs Capital Management
Maryland
$66.1M +$53.5M +307,391 New
VA
5
VR Adviser
New York
$49.6M +$40.1M +230,374 New
Citadel Advisors
6
Citadel Advisors
Florida
$38.9M +$32.1M +184,032 New
Janus Henderson Group
7
Janus Henderson Group
United Kingdom
$36.7M +$31.1M +178,715 New
O
8
OrbiMed
New York
$34M +$27.5M +158,044 New
LGM
9
Logos Global Management
California
$32.9M +$26.6M +152,966 New
SM
10
SB Management
United Arab Emirates
$30.5M +$24.7M +141,915 New
DM
11
Deerfield Management
New York
$27.9M +$22.6M +129,473 New
PA
12
Perceptive Advisors
New York
$26.9M +$21.8M +125,013 New
APM
13
Avidity Partners Management
Texas
$22.6M +$18.3M +105,071 New
BOTOTLSJU
14
Board of Trustees of The Leland Stanford Junior University
California
$21.6M +$17.5M +100,529 New
AG
15
Artal Group
Luxembourg
$21.5M +$17.4M +100,000 New
Norges Bank
16
Norges Bank
Norway
$21.5M +$17.4M +100,000 New
Federated Hermes
17
Federated Hermes
Pennsylvania
$20M +$16.2M +92,857 New
Millennium Management
18
Millennium Management
New York
$18.1M +$14.7M +84,262 New
UBS AM
19
UBS AM
Illinois
$12.1M +$9.8M +56,255 New
WP
20
Woodline Partners
California
$9.52M +$7.71M +44,246 New
Adage Capital Partners
21
Adage Capital Partners
Massachusetts
$9.22M +$7.46M +42,857 New
Jennison Associates
22
Jennison Associates
New York
$9.22M +$7.46M +42,857 New
Goldman Sachs
23
Goldman Sachs
New York
$8.43M +$6.83M +39,204 New
Morgan Stanley
24
Morgan Stanley
New York
$8.1M +$6.56M +37,643 New
CAM
25
Cormorant Asset Management
Massachusetts
$5.93M +$5.05M +29,022 New
1
2 3

LENZ Hedge Fund Activity: Q2 2021 in Review

51 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in LENZ Therapeutics (LENZ) for Q2 2021, worth a combined $981M.

Buyers outnumbered sellers: 51 funds opened new LENZ positions and 0 closed out — a net gain of 51 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Samsara BioCapital, opening a new position worth an estimated $185M.

  • 51 institutional investors held LENZ Therapeutics (LENZ) as of Q2 2021, up from 0 in Q1 2021.
  • Funds reported $981M of LENZ Therapeutics stock for Q2 2021.
  • 51 funds opened new LENZ Therapeutics positions in Q2 2021 and 0 closed out, a net change of +51 holders.
  • The largest LENZ Therapeutics buyer in Q2 2021 was Samsara BioCapital, an estimated $185M added.

Based on aggregated 13F filings for Q2 2021.